ahajournals.org7d
Abstract TP214: New Discoveries in Amyloid-Related Imaging Abnormalities with Hemorrhage (ARIA-H) and Anti-Amyloid Beta Monoclonal Antibodies
For monoclonal antibodies targeting Aβ clearance, we selected seven: Aducanumab, Bapineuzumab, Crenezumab, Donanemab, Gantenerumab, Lecanemab, and Solanezumab ... the form of monoclonal antibody ...
Nature3d
Ubiquitin-binding domains — from structures to functions
Ubiquitin-binding domains (UBDs) are modular elements that bind non-covalently to the protein modifier ubiquitin. Specific ubiquitin–UBD interactions are crucial for the regulation of multiple ...
The American Journal of Managed Care9d
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...
Business Insider6d
Biogen provides update on EU regulatory review of lecanemab in Alzheimer’s
Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD, or mild cognitive impairment due to ...
Nasdaq5d
Eisai and Biogen Provide Update on Lecanemab Regulatory Review for Alzheimer’s Disease in the European Union
Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...
Salon25d
Why Alzheimer’s scientists are rethinking the amyloid hypothesis
In June 2021, the Food and Drug Administration approved aducanumab, an amyloid beta ... It offers similar efficacy to lecanemab and comparable safety risks. To Eric Widera, a professor of medicine ...
Monthly Prescribing Reference23d
Lecanemab SC Formulation Under Review for Early Alzheimer Disease
A Prescription Drug User Fee Act target date of August 31, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...
Yahoo Finance5d
Update on regulatory review of lecanemab for treatment of early Alzheimer's disease in the European Union
These questions will now be discussed at the CHMP meeting in February 2025, before the Commission can take a final decision on the Marketing Authorization Application for lecanemab as treatment ...
clinicaladvisor.com9d
Leqembi Monthly IV Maintenance Dosing Approved for Early Alzheimer Disease
Modeling simulations predict that transitioning to once every 4 weeks of lecanemab after 18 months will maintain clinical and biomarker therapy benefits. The Food and Drug Administration (FDA ...